Apellis Pharmaceuticals Inc - Company Profile

Powered by

All the data and insights you need on Apellis Pharmaceuticals Inc in one report.

$195 $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Apellis Pharmaceuticals Inc Strategy Report

  • Understand Apellis Pharmaceuticals Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Apellis Pharmaceuticals Inc: Overview

Select Item

Related keylists

Apellis Pharmaceuticals Inc (Apellis) is a clinical-stage biopharmaceutical company that focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases through inhibition of the complement system at the level of C3 (central protein). Its pipeline product portfolio includes EMPAVELI pegcetacoplan injection for paroxysmal nocturnal hemoglobinuria disease and SYFOVRE intravitreal pegcetacoplan injection for Geographic Atrophy. Its other products include APL-1030, APL-2006 and Orala Alternative Pathway Inhibitor, among others. The company conducts research on chronic therapy with a C3 inhibitor into clinical trialsIt operates in Australia, Bermuda, the US, Germany, France, Ireland, the Netherlands, Switzerland, the UK nad Cayman Islands. Apellis is headquartered in Waltham, Massachusetts, the US.

 Gain a 360-degree view of Apellis Pharmaceuticals Inc and make more informed decisions for your business Gain a 360-degree view of Apellis Pharmaceuticals Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 100 Fifth Avenue, Waltham, Massachusetts, 02451
Website apellis.com
Telephone 1 617 9775700
No of Employees 702
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange APLS (NASD)
Revenue (2022) $396.6M 425.8% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 18.9% (2022 vs 2021)
Market Cap* $6.2B
Net Profit Margin (2022) XYZ 84.6% (2022 vs 2021)
* As of and is in US$
View Apellis Pharmaceuticals Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Apellis Pharmaceuticals Inc premium industry data and analytics

80+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Apellis Pharmaceuticals Inc’s relevant decision makers and contact details.

60+

Catalyst Calendar

Proactively evaluate Apellis Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Clinical Trials

Determine Apellis Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

14+

Pipeline Drugs

Identify which of Apellis Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

3

Marketed Drugs

Understand Apellis Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

2

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Apellis Pharmaceuticals Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
EMPAVELI (Pegcetacoplan) Injection: Paroxysmal nocturnal Hemoglobinuria
SYFOVRE (Intravitreal pegcetacoplan Injection): Geographic Atrophy
APL-1030
XYZ
XYZ
XYZ
Understand Apellis Pharmaceuticals Inc portfolio and identify potential areas for collaboration Understand Apellis Pharmaceuticals Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2023 Regulatory Approval In October, the company secured an approval from the U.S. Food and Drug Administration for EMPAVELI Injector.
2023 Contracts/Agreements In March, the company entered into an agreement with Neophth Biotechnology to jointly develop gene therapy research and development projects for retinal degenerative diseases.
2023 Regulatory Approval In February, the company announced that the U.S. Food and Drug Administration approved SYFOVRE for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters Apellis Pharmaceuticals Inc AstraZeneca Plc Amneal Pharmaceuticals Inc CytomX Therapeutics Inc Aclaris Therapeutics Inc
Headquarters United States of America United Kingdom United States of America United States of America United States of America
City Waltham Cambridge Bridgewater South San Francisco Wayne
State/Province Massachusetts England New Jersey California Pennsylvania
No. of Employees 702 89,900 7,700 120 91
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Gerald Chan Chairman Executive Board 2013 72
Cedric Francois Director; President; Chief Executive Officer Executive Board 2009 50
Timothy Sullivan Chief Financial Officer; Treasurer Senior Management 2017 52
Jim Chopas Vice President; Chief Accounting Officer; Controller Senior Management 2021 56
Karen Lewis Chief People Officer Senior Management 2020 51
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Apellis Pharmaceuticals Inc key executives to enhance your sales strategy Gain insight into Apellis Pharmaceuticals Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward